# Impact of Infection on the Lives of People with Cystic Fibrosis



A. Whitney Brown, MD Senior Director, Clinical Affairs Cystic Fibrosis Foundation



#### Cystic Fibrosis is Characterized by a Lifetime of Respiratory Infections




Inflammation




## **Prevalence of Respiratory Pathogens in CF**


Microbial Diversity by Age, Birth to 34 Years





**2019 Cystic Fibrosis Patient Registry Annual Data Report** 

#### Antimicrobial **Resistance** is a Problem in in Cystic **Fibrosis**










#### 2020 Cystic Fibrosis Patient Registry Annual Data Report

### Lessons Learned over Time: Nosocomial and Community Transmission



- Pseudomonas aeruginosa
- Burkholderia cenocepacia

Fothergill JL, Walshaw MJ, Winstanley C. Eur Resp J 2012; 40 (1): 227-238

### **Infection Prevention and Control Guidelines for CF**

- Contact precautions for all CF patients regardless of pathogen status
- Mask use by patients in common areas in health care settings
- A minimum six-foot distance between patients
- Standards for reducing infection risk with pulmonary function testing
- Auditing the cleaning and disinfection of environmental surfaces




Saiman L, et al. Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update. Infect Control Hosp Epidemiol 2014; (35)51: S1–67

## Impact of IPC Practices on People with CF




## What about the burden of infection?



**CFTR modulators: transformative therapies for cystic fibrosis Adapted from J Managed Care Spec Pharm. 2021 Feb;27(2):281-284.** 


## What happened during 2021?



	Bacteria	<b>2019</b> Percent With Infection	<b>2021</b> Percent With Infection
- Al	Pseudomonas aeruginosa	43%	28%
22	Stenotrophomonas maltophilia	12%	6%
	Methicillin-resistant Staphylococcus aureus	25%	18%
- A	Achromobacter xylosoxidans	6%	3%
\$	<i>Burkholderia cepacia</i> complex	3%	1%
N.	Nontuberculous mycobacteria	14%	10%


2021 CF Foundation Patient Registry Highlights https://www.cff.org/medical-professionals/patient-registry





Ranked 1<sup>st</sup> by people with CF and their Families among areas of focus within infection-related research for the CF Foundation (N=303)

### **CF** Foundation Microbiological Research Portfolio



# Unanswered Questions: Will the CF infection landscape change?

- With less antibiotic use, will antimicrobial resistance decrease?
- Is masking here to stay?
  - Public
  - Healthcare
- With less cough and sputum, are pathogens less transmissible?
- Can people with CF be together in person safely?



#### How will we get answers?

- Continue performing cultures
- Continue collecting data
- Keep investing in research